AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer

by Dunne, P.D., McArt, D.G., Blayney, J.K., Kalimutho, M., Greer, S., Wang, T., Srivastava, S., Ong, C.W., Arthur, K., Loughrey, M., Redmond, K., Longley, D.B., Salto-Tellez, M., Johnston, P.G., Van Schaeybroeck, S.
Published 2014